GTS-21
Sign in to saveAlso known as 3-(2,4-dimethoxybenzylidene)anabaseine, Dimethoxybenzylidene anabaseine, DMXB-A, DMXB-Anabaseine
GTS-21 (also known as DMXBA or DMBX-anabaseine) is an investigational new drug being studied for the treatment of neurodegenerative diseases and psychiatric disorders, as well as for its potential to enhance memory and cognitive function. Despite study of the molecule since 1990s, as of 2025 it has not been shown to be effective in clinical trials.
Research
280 papers- GTS-21 alleviates sepsis-induced atrial fibrillation susceptibility by modulating macrophage polarization and Neuregulin-1 secretion.International immunopharmacology · 2025
- GTS-21 alleviates murine collagen-induced arthritis through inhibition of peripheral monocyte trafficking into the synovium.International immunopharmacology · 2023
- GTS-21 has cell-specific anti-inflammatory effects independent of α7 nicotinic acetylcholine receptors.PloS one · 2019
- GTS-21 ameliorates polymicrobial sepsis-induced hepatic injury by modulating autophagy through α7nAchRs in mice.Cytokine · 2020
- GTS-21 reduces microvascular permeability during experimental endotoxemia.Microvascular research · 2018
via PubMed
Wikidata facts
- Mass
- 308.152
Show 4 more facts
- chemical formula
- C₁₉H₂₀N₂O₂
- canonical SMILES
- COC1=CC(=C(C=C1)C=C2CCCN=C2C3=CN=CC=C3)OC
- isomeric SMILES
- COC1=CC(=C(C=C1)/C=C/2\CCCN=C2C3=CN=CC=C3)OC
- Commons category
- GTS-21
Sources (2)
via Wikidata · CC0
~2 min read
Article
3 sectionsContents
- Research and clinical trial history
- References
- Further reading
GTS-21 (also known as DMXBA or DMBX-anabaseine) is an investigational new drug being studied for the treatment of neurodegenerative diseases and psychiatric disorders, as well as for its potential to enhance memory and cognitive function. Despite study of the molecule since 1990s, as of 2025 it has not been shown to be effective in clinical trials.
GTS-21 is a derivative of the natural product anabaseine that acts as a partial agonist at neural nicotinic acetylcholine receptors (nAChRs). It binds to both the α4β2 and α7 subtypes, but activates only the α7 to any significant extent. Activation of the α7 nAChR has been shown to have neuroprotective effects which has made GTS-21 a focus of research in the treatment of neurological diseases.